UCB acquires Lectus Therapeutics’ key pharmaceutical assets
UCB has acquired Lectus Therapeutics’s key pharmaceutical assets via a licence and acquisition agreement. Lectus Therapeutics Ltd is a drug discovery and development company focusing on next-generation ion channel modulators. The transaction involves the acquisition of all the company’s drug discovery and development programmes targeting ion channels for the treatment of a specific set of CNS indications (Central Nervous System). Financial details of the transaction were not disclosed.
Under the terms of the agreement UCB will also gain exclusive worldwide rights to commercialise products discovered from the use of Lectus’s proprietary LEPTICS® technology for a number of further ion channel targets.
The drug discovery and development programmes acquired by UCB centre on the use of Lectus’s proprietary LEPTICS® technology to identify compounds in a new area of chemical space. Such compounds are anticipated to possess a novel mechanism of action mediated through an effect on ion channel accessory proteins.
Other news from the department business & finance
